The iCMLf is a charitable foundation established by a group of hematologists with a strong interest in Chronic Myeloid Leukemia (CML). The mission of the iCMLf is to improve the outcomes for patients with CML globally. It aims to foster and coordinate global clinical and research collaborations and to improve clinical practice and disease monitoring in CML. Scientific advisors and national representatives spanning over 30 countries provide guidance and advice to further the aims of the iCMLf. Read more here.
Professor Jane Apperley becomes a new member of the iCMLf Board of
The iCMLf is delighted to announce that Professor Jane Apperley has accepted our invitation to join the iCMLf Board of Directors as a new member. “She is a leading expert in CML monitoring and management and has been a strong supporter of the Foundation through her work with preceptors at the Hammersmith Hospital”, said Tim Hughes, chair of the iCMLf.
In 2012/2013 the iCMLf’s Emerging Regions Support and Partnership (ERSAP) Clinical Preceptorship Program provided a unique opportunity for 26 preceptors from emerging economic regions to undertake intensive education programs. Individual preceptorships were held over 3-4 weeks at CML centres of excellence.
Over the coming months we will share some of the interesting experiences from the 2012/13 preceptors that clearly demonstrate what they learn from their stay at the CML centre of excellence overseas and what they can implement back home.
iCMLf Forum 2013: Webstreams of presentations now available
Webstreams of all presentations of the International CML Foundation Forum, held in partnership with The Max Foundation during the meeting of the American Society of Hematology (ASH) in New Orleans on 6 December 2013, are now available.
Following the sudden death of Professor John Goldman the iCMLf Directors have
nominated Professor Tim Hughes as the next chairman of the foundation. Dr Hughes is one of the co-founders of the Foundation and has helped to shape the iCMLf’s strategy and programs for the past five years as member of the Board of Directors.
The recently launched new module of the iCMLf’s Virtual Education Program presents the results of a global survey on the non-adherence of CML patients – a key problem in CML. The survey conducted by the CML Advocates Network evaluated data from 2,546 CML patients from 79 countries.
The webcast is presented by Giora Sharf, co-founder of the CML Advocates Network and President of the Israeli CML Patient Organization.
In addition to the Rowley Prize that the iCMLf awards annually to individuals that have made a major lifetime contribution to the understanding of the biology of CML, the iCMLf Directors have created a second prize. The recently launched Goldman Prize complements the Rowley Prize as a clinical equivalent by recognising lifetime contributions to the management of patients with CML. The new award has been created in memory of the late iCMLf chair to honour Professor Goldman´s commitment to clinical excellence in treating CML.
In 2014 the iCMLf Rowley Prize for persons who have made major contributions to understanding the biology of CML is awarded to Dr Owen Witte, a Distinguished Professor of Microbiology, Immunology and Molecular genetics. Dr Witte is Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles (UCLA) and a Howard Hughes Medical Institute Investigator. He currently holds the UCLA Presidential Chair in Developmental Immunology.
It is with great sorrow that the iCMLf has learned of the death of Professor John Goldman, after a short illness.
With a worldwide reputation in the study of the biology and treatment of CML, John was a true leader, teacher and inspiration to so many.